Co-Authors
This is a "connection" page, showing publications co-authored by Stefan Pöhlmann and Marcel Müller.
Connection Strength
1.182
-
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature. 2020 09; 585(7826):588-590.
Score: 0.223
-
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. Antimicrob Agents Chemother. 2020 05 21; 64(6).
Score: 0.221
-
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 04 16; 181(2):271-280.e8.
Score: 0.218
-
Inhibition of proprotein convertases abrogates processing of the middle eastern respiratory syndrome coronavirus spike protein in infected cells but does not reduce viral infectivity. J Infect Dis. 2015 Mar 15; 211(6):889-97.
Score: 0.147
-
Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol. 2011 Dec; 85(24):13363-72.
Score: 0.122
-
Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011 May; 85(9):4122-34.
Score: 0.116
-
Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus. Emerg Microbes Infect. 2020; 9(1):155-168.
Score: 0.054
-
Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization. J Virol. 2019 01 15; 93(2).
Score: 0.050
-
The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 2011 Oct; 7(10):e1002331.
Score: 0.030